Lophius raises €4.25m from Bayern Kapital et al.
Bayern Kapital and private investors Wolfs Biotech and WIC have backed a €4.25m round for German biotech business Lophius.
Lophius will use the proceeds to continue development of its T cell-based research tools and expand the company's in-vitro diagnostic programs to tuberculosis. The business stated there are 9.5 million new tuberculosis cases per year worldwide and 450,000 cases reported for Europe.
Bayern Kapital manages 11 investment funds with a total volume of €340m. So far, it has invested €227m in 245 technology companies in sectors including life sciences, software and IT, medical technology, nanotechnology and environmental technology.
Company
Founded in 2002 and based in Regensburg, Lophius Biosciences is a biotech company developing T cell-based research tools, doing contract research and diagnostics for functional assessment of pathogen/disease-reactive T cells.
The company aims to improve therapy control and personalised treatment of patients in the areas of transplantation medicine, infectious and autoimmune diseases.
People
Bayern Kapital – Roman Huber (managing director).
Lophius – Robert Phelps, Bernd Merkl (co-CEOs, managing directors).
VRD – Thomas Hartwig (managing director).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater